Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Securities code: 603567 Securities abbreviation: Zhenbaodao
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
2025 Third Quarter Report
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The company's board of directors, directors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) guarantee that the financial information in the quarterly report is true, accurate and complete.
Whether the third quarter financial statements have been audited
□Yes √No
1. Main financial data
(1) Main accounting data and financial indicators
Unit: Yuan Currency: RMB This reporting period increased from the beginning of the reporting period to the same period last year. Items at the end compared with the same period last year During this reporting period From the beginning of the reporting period to the end of the reporting period
Decrease the range of change Increase or decrease the range of change
(%) (%) Operating income 204,775,131.76 -44.14 918,186,023.95 -54.71 Total profit -350,538,468.09 -456.59 -464,947,127.37 -205.99 Attributable to shareholders of listed companies
-294,808,449.23 -6,798.17 -373,098,345.72 -193.81 net profit
Attributable to shareholders of listed companies
Net profit after deducting non-recurring gains and losses -318,408,443.99 -5,234.92 -402,189,533.39 -212.93
Cash generated from operating activities
Not applicable Not applicable 223,271,909.47 Not applicable Net flow
Basic earnings per share (yuan/share) -0.3136 -6,917.39 -0.3969 -193.76 Diluted earnings per share (yuan/share) -0.3136 -6,917.39 -0.3969 -193.92 Weighted average net asset income decreased by 3.94 units decreased by 10.03 units
-3.89 -4.90
Rate (%) percentage point percentage point
1/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
The end of the reporting period is more or less than the end of the reporting period compared with the end of the previous year.
Change (%) Total assets 11,796,553,751.25 12,712,631,463.50 -7.21 Attributable to shareholders of listed companies
Owner’s equity of 7,288,279,720.76 7,800,611,827.44 -6.57
Note: "This reporting period" refers to the three-month period from the beginning of this quarter to the end of this quarter, the same below.
(2) Non-recurring profit and loss items and amounts
√Applicable □Not applicable
Unit: Yuan Currency: RMB Non-recurring profit and loss items from the beginning of the year to the end of the reporting period Amount for the period Description
Amount of gains and losses on disposal of non-current assets, including accrued
-519,863.16 -519,863.16 Offset portion of asset impairment provisions
Government subsidies included in the current profit and loss, but with the company
Closely related to normal business operations and in compliance with national policies
30,163,254.17 40,065,581.71 Government subsidies that have a lasting impact on the company’s profits and losses are excluded from the policy provisions, are enjoyed according to determined standards, and have a lasting impact on the company’s profits and losses.
Outside
Except for those related to the company’s normal business operations,
In addition to hedging business, non-financial enterprises hold gold
Fair value of financial assets and financial liabilities 29,846.18 -73,467.52 changes in profits and losses and disposal of financial assets and financial
Gains and losses from liabilities
Charges charged to non-financial enterprises included in current profits and losses
capital occupation fee
Gains and losses from entrusting others to invest or manage assets
Profit and loss from external entrusted loans
Due to force majeure factors, such as natural disasters
Various asset losses incurred
Impairment of receivables subject to separate impairment test
Prepare to transfer back
Enterprises acquire subsidiaries, associates and joint ventures
The investment cost of the business is less than the entitlement when obtaining the investment
There is a fair value of identifiable net assets of the investee.
income generated by value
Subsidiaries resulting from business combinations under common control
Net profit and loss for the period from the beginning of the period to the date of merger
Gains and losses on non-monetary asset exchanges
Debt restructuring gains and losses
The enterprise becomes liable because the relevant business activities are no longer sustainable.
One-time expenses incurred, such as employee placement expenses
2/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Wait
Due to adjustments in taxation, accounting and other laws and regulations,
One-time impact on current profit and loss
Due to the cancellation and modification of the equity incentive plan, the one-time confirmation
share-based payment fees
For cash-settled share-based payments, the
After that date, the fair value of employee compensation payable will change
Profit and loss arising from activities
Adopting the fair value model for subsequent measurement
Changes in fair value of investment real estate
Profit and loss
Income arising from transactions where the transaction price is unfair
benefit
Contingencies unrelated to the company's normal business operations
Profit and loss arising from item
Custody fee income from entrusted operations
Other non-operating income other than the above items
-1,883,810.75 -5,384,334.30 and expenses
Other gains and losses that meet the definition of non-recurring gains and losses
Project
Less: Impact on income tax 4,189,593.34 4,996,729.06 Impact on minority shareholders’ equity (after tax) -161.66
Total 23,599,994.76 29,091,187.67
If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable
(3) Changes in main accounting data and financial indicators and reasons √Applicable □Not applicable
Project name Change ratio (%) Main reasons
Mainly due to ① The shipment volume in this period did not meet expectations; ② The main product price operating income in this period_this reporting period -44.14
Due to the drop in price. Total profit_this reporting period -456.59
Attributable to shareholders of listed companies
-6,798.17
Net profit_this reporting period is mainly due to the reduction in sales scale in the current period, the increase in losses attributable to shareholders of listed companies due to credit impairment of delayed customer repayments, and the decrease in the realizable value of inventories. Net of non-recurring gains and losses -5,234.92
Profit_this reporting period
Basic earnings per share (yuan/share)_
-6,917.39
This reporting period was mainly due to the decrease in net profits attributable to shareholders of listed companies. Diluted earnings per share (yuan/share)_ -6,917.39
3/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
this reporting period
Operating income_from the beginning of the year to the reporting period is mainly due to ① due to the delay in the implementation of the national centralized procurement of proprietary Chinese medicines.
-54.71
The volume of goods at the end of the period decreased; ② due to the decrease in prices of main products in this period. Total profit_from the beginning of the year to the reporting period
-205.99
end
Attributable to shareholders of listed companies
-193.81 Mainly due to the reduction in sales scale in the current period and credit impairment net profit from customers’ delayed payment collection_from the beginning of the year to the end of the reporting period
Due to the increase in losses and the decrease in the realizable value of inventories. Attributable to shareholders of listed companies
Net of non-recurring gains and losses -212.93
Profit_from the beginning of the year to the end of the reporting period
Basic earnings per share (yuan/share)_
-193.76
From the beginning of the year to the end of the reporting period
Mainly due to the decrease in net profits attributable to shareholders of listed companies. Diluted earnings per share (yuan/share)_
-193.92
From the beginning of the year to the end of the reporting period
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Total number of ordinary shareholders at the end of the reporting period Total number of preference shareholders with restored voting rights at the end of the reporting period
20,893 0 number (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Shareholding ratio of pledged, marked or frozen conditions Holding of sales restrictions
Name of shareholder Nature of shareholder Number of shares held
Example (%) Number of shares
Number of share certificates
State Heilongjiang Chuangda Group Co., Ltd. Domestic non-state-owned
470,985,300 50.05 0 Pledge 457,319,014 Division Legal person
Heilongjiang Chuangda Group Co., Ltd.
Division-Oriented to professional investors in 2023
Exchangeable non-public issuance by investors Others 84,772,958 9.01 0 No corporate bonds (first phase) pledge
Special deposit account
Bozhou Junze Fanglong Equity Investment Domestic non-state-owned
48,398,200 5.14 0 Centerless (limited partnership) Legal person
Huzhou Saihan Equity Investment Partnership Domestic non-state-owned
47,049,826 5 0 No business (limited partnership) Legal person
Shanghai Shengzhong Investment Management Co., Ltd.
Company-Shaoxing Binhai New Area Student
Others 11,069,055 1.18 0 Wuwu Pharmaceutical Industry Equity Investment Fund
Golden Partnership (Limited Partnership)
Heilongjiang Chuangda Group Co., Ltd.
Others 7,576,056 0.81 0 None - For professional investors in 2023
4/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Non-public issuance by investors is exchangeable
Corporate Bond (Second Issue) Pledge
Special deposit account
Chen Jingrong Domestic natural person 5,683,044 0.60 0 None
Liu Yanxiang Domestic natural person 5,604,300 0.60 0 None
Li Zuowang Domestic natural person 5,581,048 0.59 0 None
Lei Heyin Domestic natural persons 5,560,000 0.59 0 None
Shareholding status of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing)
Type and quantity of shares
Name of shareholder Number of shares held without selling restrictions
Share Type Quantity
Heilongjiang Chuangda Group Co., Ltd.
470,985,300 RMB ordinary shares 470,985,300 Division
Heilongjiang Chuangda Group Co., Ltd.
Division-Oriented to professional investors in 2023
Exchangeable non-public issuance by investors 84,772,958 RMB ordinary shares 84,772,958 corporate bonds (first phase) pledge
Special deposit account
Bozhou Junze Fanglong Equity Investment
48,398,200 RMB ordinary shares 48,398,200 Center (limited partnership)
Huzhou Saihan Equity Investment Partnership
47,049,826 RMB ordinary shares 47,049,826 Enterprises (limited partnership)
Shanghai Shengzhong Investment Management Co., Ltd.
Company-Shaoxing Binhai New Area Student
11,069,055 RMB ordinary shares 11,069,055 Biopharmaceutical Industry Equity Investment Fund
Golden Partnership (Limited Partnership)
Heilongjiang Chuangda Group Co., Ltd.
Division-Oriented to professional investors in 2023
Exchangeable non-public issuance by investors 7,576,056 RMB ordinary shares 7,576,056 corporate bonds (second tranche)
Special deposit account
Chen Jingbong 5,683,044 RMB ordinary shares 5,683,044 Liu Yanxiang 5,604,300 RMB ordinary shares 5,604,300 Li Zuowang 5,581,048 RMB ordinary shares 5,581,048 Lei Heyin 5,560,000 RMB ordinary shares 5,560,000 among the above shareholders are Heilongjiang Chuangda Group Co., Ltd., Bozhou Junze Fanglong Equity Investment Center (Limited Partnership) and Hu
There is no related relationship or concerted action among the three shareholders of Zhou Saihan Equity Investment Partnership (Limited Partnership). The above-mentioned shareholder related relationship or a
Explanation of the actions taken by Heilongjiang Chuangda Group Co., Ltd., Bozhou Junze Fanglong Equity Investment Center (Limited Partnership) and Huzhou Saihan Equity
If there is no related relationship or concerted action between the investment partnership (limited partnership) and the remaining shareholders, the company shall
The company does not know whether there are related relationships or persons acting in concert among the remaining shareholders.
Top 10 shareholders and top 10
No selling shareholders are allowed to participate in financing
None
The situation of securities and refinancing business
Ming (if any)
5/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares □ Applicable √ Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable √Not applicable
3. Other reminders
Investors need to be reminded of other important information regarding the company’s operations during the reporting period.
□Applicable √Not applicable
4. Quarterly Financial Statements
(1) Types of audit opinions
□Applicable √Not applicable
(2) Financial statements
Consolidated Balance Sheet
September 30, 2025
Prepared by: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Items September 30, 2025 Current assets on December 31, 2024:
Monetary funds 203,820,560.49 1,053,304,072.43 Settlement reserves
Loan funds
Trading financial assets 463,763.72 537,231.24 Derivative financial assets
Notes receivable 4,746,195.42 48,421,100.68 Accounts receivable 3,106,495,052.90 3,093,309,025.42 Accounts receivable financing 3,280,886.06 5,775,880.52 Prepayments 90,584,217.74 90,279,907.65 Premiums receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 1,008,150,233.01 1,085,200,915.63 Including: interest receivable
Dividends receivable
Buy financial assets under resale agreements
Inventory 1,521,134,634.72 1,488,080,420.91 Including: data resources
6/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Contract assets 8,963,827.86 8,963,827.86 Assets held for sale
Non-current assets due within one year 5,703,779.20 15,389,665.40 Other current assets 306,643,531.41 303,797,066.54
Total current assets 6,259,986,682.53 7,193,059,114.28 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
long-term receivables
Long-term equity investment 721,809,182.38 707,060,226.71 Other equity instrument investment 591,200,000.00 591,200,000.00 Other non-current financial assets
Investment real estate 799,402,501.02 814,729,707.85 Fixed assets 1,235,616,095.58 1,318,984,887.08 Construction in progress 158,118,943.26 149,415,977.64 Productive biological assets
oil and gas assets
Right-of-use assets 9,492,287.02 12,330,812.78 Intangible assets 1,030,575,361.51 980,366,925.94 Including: data resources
Development expenditure 211,130,123.04 203,600,771.65 including: data resources
Goodwill 14,823,926.83 14,823,926.83 Long-term deferred expenses 33,634,702.13 42,458,973.10 Deferred income tax assets 440,330,407.32 321,117,330.32 Other non-current assets 290,433,538.63 363,482,809.32 Total non-current assets 5,536,567,068.72 5,519,572,349.22
Total assets 11,796,553,751.25 12,712,631,463.50 Current liabilities:
Short-term borrowings 1,462,548,232.21 1,296,020,868.06 Borrowings from the central bank
borrowing funds
Trading financial liabilities
Derivative financial liabilities
Notes payable
Accounts payable 314,776,539.17 278,162,437.19 Advance receipts 59,961,740.17 5,538,355.49 Contract liabilities 153,774,980.26 49,759,820.64 Financial assets sold under repurchase agreements
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
7/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Agent underwriting securities funds
Employee benefits payable 36,507,921.98 29,686,282.99 Taxes payable 95,679,096.29 137,047,509.01 Other payables 196,845,976.56 227,045,546.49 Including: interest payable
Dividends payable
Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 1,218,066,603.92 444,157,028.89 Other current liabilities 18,622,120.90 52,858,274.16
Total current liabilities 3,556,783,211.46 2,520,276,122.92 Non-current liabilities:
insurance contract reserves
Long-term borrowings 607,000,000.00 1,546,000,000.00 Bonds payable
Among them: preferred shares
perpetual bond
Lease liabilities 7,436,790.34 7,966,075.14 Long-term payables
Long-term employee benefits payable
Estimated liabilities 158,494,642.39 158,494,642.39 Deferred income 141,041,677.55 150,107,169.09 Deferred income tax liabilities 37,594,593.29 37,913,406.94 Other non-current liabilities 808,376.04 808,375.54 Total non-current liabilities 952,376,079.61 1,901,289,669.10
Total liabilities 4,509,159,291.07 4,421,565,792.02 Owners’ equity (or shareholders’ equity):
Paid-in capital (or equity) 940,996,515.00 941,140,609.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 2,338,408,378.78 2,338,588,481.93 Less: treasury shares 13,885,131.38 15,100,131.98 Other comprehensive income
Special reserves 7,191,513.95 4,985,730.89 Surplus reserves 471,012,700.08 471,012,700.08 General risk reserves
Undistributed profits 3,544,555,744.33 4,059,984,437.52 Attributable to the parent company’s owner’s equity (or shareholder’s rights
7,288,279,720.76 7,800,611,827.44 profit) total
Minority interests -885,260.58 490,453,844.04
8/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Total owners’ equity (or shareholders’ equity) 7,287,394,460.18 8,291,065,671.48 Liabilities and owners’ equity (or shareholders’ equity)
11,796,553,751.25 12,712,631,463.50Total
Person in charge of the company: Yan Jiujiang Person in charge of accounting work: Zhang Yanwei Person in charge of the accounting department: Zhang Yanwei
consolidated income statement
January-September 2025
Prepared by: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited Projects for the first three quarters of 2025 and the first three quarters of 2024
(January-September) (January-September)
- Total operating income 918,803,288.12 2,029,396,710.78 Including: operating income 918,186,023.95 2,027,206,914.41 Interest income 617,264.17 2,189,796.37 Premiums earned
Fee and commission income
- Total operating costs 1,063,804,640.08 1,516,630,249.21 Including: operating costs 590,292,703.76 950,734,675.89 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
Reinsurance cost
Taxes and surcharges 25,193,474.13 40,772,789.68 Sales expenses 99,079,013.92 195,180,411.22 Management expenses 217,065,904.44 220,815,744.54 Research and development expenses 19,522,837.29 15,794,348.20 Financial expenses 112,650,706.54 93,332,279.68 Including: interest expenses 114,565,540.85 103,952,495.89
Interest income 5,913,182.93 17,735,402.95 plus: other income 42,124,444.67 44,172,645.24 Investment income (losses are listed with "-") -5,501,044.33 -4,765,997.35 Including: investments in associates and joint ventures
-5,501,044.33 -18,515,998.35 capital income
Financial instruments measured at amortized cost
Income from derecognition of assets
Exchange gains (losses are listed with "-")
Net exposure hedging income (losses are filled in with "-"
column)
Gains from changes in fair value (losses marked with “-” -73,467.52 45,917.20
9/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Fill in the column)
Credit impairment losses (losses are listed with "-") -185,370,266.60 -50,460,078.71 Asset impairment losses (losses are listed with "-") -165,221,244.17 -60,664,678.09
Asset disposal income (losses are listed with "-") -519,863.16 -1,512,901.49
- Operating profit (losses are listed with "-") -459,562,793.07 439,581,368.37 plus: non-operating income 1,220,482.69 1,891,860.10
Less: Non-operating expenses 6,604,816.99 2,785,155.60
- Total profits (total losses are listed with "-") -464,947,127.37 438,688,072.87
Less: Income tax expense -89,308,222.52 42,253,434.21
- Net profit (net loss is listed with "-") -375,638,904.85 396,434,638.66
(1) Classification by business continuity
- Net profit from continuing operations (net loss is marked with "-"
-375,638,904.85 396,434,638.66 fill in the column)
- Net profit from discontinued operations (net loss is marked with "-"
Fill in the column)
(2) Classification according to ownership ownership
- Net profit attributable to shareholders of the parent company (net
-373,098,345.72 397,733,293.18 Losses are listed with a “-” sign)
- Profit and loss of minority shareholders (net loss is filled in with "-"
-2,540,559.13 -1,298,654.52 columns)
6. Net amount of other comprehensive income after tax
(1) Other comprehensive income attributable to owners of the parent company
net profit after tax
- Other comprehensive income that cannot be reclassified into profit or loss
(1) Remeasurement of changes in defined benefit plan
(2) Other comprehensive assets that cannot be transferred to profit or loss under the equity method
combined income
(3) Changes in fair value of investments in other equity instruments
move
(4) Changes in the fair value of the enterprise’s own credit risk
move
- Other comprehensive income that will be reclassified into profit and loss
(1) Other comprehensive convertible profits and losses under the equity method
income
(2) Changes in fair value of other debt investments
(3) Financial assets are reclassified into other comprehensive
Amount of income
(4) Credit impairment provisions for other debt investments
(5) Cash flow hedging reserve
(6) Translation differences of foreign currency financial statements
(7) Others
(2) Other comprehensive income attributable to minority shareholders
10/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
net of tax
- Total comprehensive income -375,638,904.85 396,434,638.66
(1) Comprehensive income attributable to owners of the parent company
-373,098,345.72 397,733,293.18 total
(2) Total comprehensive income attributable to minority shareholders -2,540,559.13 -1,298,654.52
8. Earnings per share:
(1) Basic earnings per share (yuan/share) -0.3969 0.4233
(2) Diluted earnings per share (yuan/share) -0.3969 0.4226
If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.
Person in charge of the company: Yan Jiujiang Person in charge of accounting work: Zhang Yanwei Person in charge of the accounting department: Zhang Yanwei
Consolidated Cash Flow Statement
January-September 2025
Prepared by: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited Projects for the first three quarters of 2025 and the first three quarters of 2024
(January-September) (January-September)
1. Cash flow generated from operating activities:
Cash received from selling goods and providing services 1,291,395,030.87 1,485,758,005.68 Net increase in customer deposits and deposits from banks
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions 487,804.84 2,300,945.37 Net increase in borrowed funds
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
tax refund received
Other cash received related to operating activities 154,133,837.44 488,736,406.07
Subtotal of cash inflows from operating activities 1,446,016,673.15 1,976,795,357.12 Cash paid for purchasing goods and receiving services 569,427,398.50 1,235,048,552.08 Net increase in customer loans and advances 5,120,000.00 Net increase in deposits with the central bank and inter-bank payments
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 160,371,082.65 261,274,423.34 Various taxes and fees paid 115,509,542.86 297,933,832.26 Cash paid for other operating activities 377,436,739.67 349,317,243.68
11/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Subtotal of cash outflows from operating activities 1,222,744,763.68 2,148,694,051.36
Net cash flow generated from operating activities 223,271,909.47 -171,898,694.24
2. Cash flow generated from investing activities:
Recover cash received on investments
Cash received from investment income 13,750,000.00 Disposal of fixed assets, intangible assets and other long-term assets
1,094,907.61 707,304.21 Net cash recovered from property
Disposal of cash received from subsidiaries and other business units
122,000,001.00 net amount
Other cash received related to investing activities
Subtotal of cash inflows from investing activities 1,094,907.61 136,457,305.21 Purchase and construction of fixed assets, intangible assets and other long-term assets
65,519,934.01 67,919,336.30 Cash paid
Cash paid for investment 520,622,123.77 42,150,000.00 Net increase in pledged loans
Obtain cash payments from subsidiaries and other business units
Net amount of money
Other cash payments related to investing activities
Subtotal of cash outflows from investing activities 586,142,057.78 110,069,336.30
Net cash flow generated from investing activities -585,047,150.17 26,387,968.91
3. Cash flow generated from financing activities:
Absorbing cash received from investments
Among them: the amount received by the subsidiary from absorbing investment from minority shareholders
Cash
Cash received from borrowings 1,415,000,000.00 1,280,000,000.00 Cash received from other financing activities 1,829,395.02 7,382,173.70
Subtotal of cash inflows from financing activities 1,416,829,395.02 1,287,382,173.70 Cash paid to repay debts 1,655,740,000.00 1,302,000,000.00 Cash paid to distribute dividends, profits or pay interest 244,967,759.96 291,784,585.21 including: dividends paid by subsidiaries to minority shareholders,
profit
Cash payments related to other financing activities 1,930,115.20 51,096,763.41 Subtotal of cash outflows from financing activities 1,902,637,875.16 1,644,881,348.62
Net cash flow generated from financing activities -485,808,480.14 -357,499,174.92
4. The impact of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents -847,583,720.84 -503,009,900.25 Plus: opening balance of cash and cash equivalents 1,050,313,244.04 1,446,189,089.17
Balance of cash and cash equivalents at the end of the period 202,729,523.20 943,179,188.92 Person in charge of the company: Yan Jiujiang Person in charge of accounting work: Zhang Yanwei Person in charge of the accounting department: Zhang Yanwei
The first implementation of new accounting standards or standard interpretations starting in 2025 will involve adjustments to the financial statements at the beginning of the year of first implementation.
□Applicable √Not applicable
12/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Announcement is hereby made.
Board of Directors of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
October 28, 2025
13/13